The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

CORONARY INTERVENTIONS

Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)

EuroIntervention 2018;14:e1224-e1226 published online November 2018 published online e-edition December 2018. DOI: 10.4244/EIJ-D-18-00839

1. Amsterdam University Medical Center, Amsterdam, the Netherlands; 2. Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; 3. Complejo Hospitalario Universitario, Hospital Alvaro Cunqueiro, Vigo, Spain; 4. Department of Cardiology, Odense University Hospital, Odense C, Denmark; 5. Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, Barcelona, Spain; 6. Department of Cardiology, Medical Centre Leeuwarden, Leeuwarden, the Netherlands; 7. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; 8. Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands; 9. Hospital Clinic, Institut Clinic Cardiovascular, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; 10. Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 11. NHLI, Imperial College London, London, United Kingdom

Previous midterm follow-up reports after implantation of the Absorb™ everolimus-eluting bioresorbable scaffold (BRS; Abbott Vascular, Santa Clara, CA, USA) in stable coronary artery disease and acute coronary syndrome have shown an increase of scaffold thrombosis leading to an excess of the device-oriented composite endpoint (DOCE: a composite of cardiac death, target vessel myocardial infarction [TVMI], and clinically driven target lesion revascularisation [CD-TLR])1. In contrast, in the six-month primary report of ABSORB STEMI: the TROFI II Study (NCT01986803)2, which randomised patients with ST-elevation myocardial infarction (STEMI) to receive either the Absorb BRS or the XIENCE metallic everolimus-eluting stent (EES; Abbott Vascular), optical frequency domain imaging (OFDI)-derived healing score was comparable between the BRS arm and the EES arm. The aim of this report was to present the three-year clinical outcome results of the BRS and the metallic EES at the time when full resorption of the scaffold device can be expected.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee